| 000 | 01757 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513224914.0 | ||
| 264 | 0 | _c20010531 | |
| 008 | 200105s 0 0 eng d | ||
| 022 | _a0951-3590 | ||
| 024 | 7 |
_a10.3109/09513590009167706 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPeichl, P | |
| 245 | 0 | 0 |
_aSerum osteocalcin and urinary crosslaps are suitable markers of bone turnover in response to short-term hormone replacement therapy. _h[electronic resource] |
| 260 |
_bGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology _cOct 2000 |
||
| 300 |
_a374-81 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAmino Acids _xurine |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aBone Resorption |
| 650 | 0 | 4 |
_aCollagen _xurine |
| 650 | 0 | 4 | _aEstrogen Replacement Therapy |
| 650 | 0 | 4 |
_aEstrogens _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFollicle Stimulating Hormone _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLuteinizing Hormone _xblood |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNorethindrone _xadministration & dosage |
| 650 | 0 | 4 |
_aOsteocalcin _xblood |
| 650 | 0 | 4 |
_aOsteogenesis _xdrug effects |
| 650 | 0 | 4 |
_aPeptide Fragments _xurine |
| 650 | 0 | 4 | _aPostmenopause |
| 700 | 1 | _aGriesmacher, A | |
| 700 | 1 | _aMüller, M M | |
| 700 | 1 | _aMarteau, R | |
| 700 | 1 | _aKumpan, W | |
| 700 | 1 | _aBröll, H | |
| 773 | 0 |
_tGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology _gvol. 14 _gno. 5 _gp. 374-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/09513590009167706 _zAvailable from publisher's website |
| 999 |
_c11051260 _d11051260 |
||